communityacquir
pneumonia
cap
common
diseas
repres
frequent
caus
hospit
admiss
mortal
infecti
origin
develop
countri
recent
despit
avail
mani
diagnost
techniqu
nearli
half
case
cap
remain
undiagnos
repres
risk
inappropri
antimicrobi
therapi
etiolog
investig
cap
tradit
focus
bacteri
agent
littl
attent
paid
viral
caus
number
reason
brought
forward
explain
first
still
unclear
whether
viru
caus
pneumonia
whether
viru
act
conjunct
respiratori
pathogen
second
diagnosi
difficult
primarili
method
use
recent
cultur
immunofluoresc
viral
antigen
serolog
expens
often
unavail
third
absenc
specif
antivir
agent
adult
influenza
remain
predomin
viral
caus
cap
howev
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
guidelin
cap
includ
commonli
recognis
virus
respiratori
syncyti
viru
rsv
adenoviru
parainfluenza
viru
well
less
common
virus
includ
human
metapneumoviru
herp
simplex
viru
varicellazost
viru
sever
acut
respiratori
syndrom
sar
associ
coronaviru
measl
viru
recent
polymeras
chain
reaction
pcr
base
method
develop
diagnosi
mani
bacteri
larg
number
viral
respiratori
pathogen
studi
aim
describ
aetiolog
cap
patient
admit
hospit
describ
clinic
laboratori
featur
patient
bacteri
pneumonia
bp
compar
viral
pneumonia
vp
pandem
year
prospect
observ
studi
conduct
hospit
universitari
mutua
terrassa
acut
care
hospit
approxim
admissionsyear
popul
inhabit
novemb
octob
consecut
adult
cap
admit
hospit
least
h
monday
friday
includ
patient
good
qualiti
respiratori
sampl
microbiolog
analysi
includ
cap
defin
acut
ill
radiograph
pulmonari
shadow
confirm
one
clinician
one
radiologist
least
two
follow
fever
cough
dyspnoea
sputum
product
pleurit
chest
pain
shake
chill
exclus
criteria
age
year
pneumonia
distal
endobronchi
obstruct
pulmonari
tuberculosi
bronchiectasi
nosocomi
pneumonia
admiss
data
prospect
collect
includ
demograph
characterist
smoke
comorbid
charlson
score
prognosi
measur
pneumonia
sever
index
psi
curb
score
confus
urea
mmoll
respiratori
rate
breath
permin
blood
systol
pressur
mm
hg
diastol
mm
hg
immunosuppress
condit
clinic
featur
biomark
creactiv
protein
crp
procalcitonin
pct
empir
definit
antimicrobi
therapi
length
stay
inhospit
mortal
defin
immunosuppress
patient
current
chemotherapi
biolog
therapi
chronic
system
steroid
use
mgd
day
equival
dose
neutropaenia
hiv
count
less
studi
conduct
accord
ethic
principl
set
latest
version
declar
helsinki
standard
use
good
clinic
practic
approv
hospit
ethic
research
committe
written
inform
consent
obtain
patient
baselin
two
set
blood
cultur
obtain
patient
prior
commenc
antibiot
therapi
blood
cultur
process
system
marcyetoil
franc
nasopharyng
swab
specimen
diagnosi
influenza
pandem
strain
collect
pandem
sputum
sampl
process
gram
stain
sampl
contain
predomin
polymorphonuclear
leukocyt
squamou
epitheli
cell
consid
accept
cultur
viral
rna
dna
extract
sputum
sampl
use
kit
seeplex
ace
detect
follow
manufactur
instruct
pcr
perform
sputum
sampl
legionella
pneumophila
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
multiplex
pcr
respiratori
virus
detect
capillari
electrophoresi
influenza
b
rsv
b
parainfluenza
coronaviru
rhinoviru
b
adenoviru
metapneumoviru
bocaviru
enteroviru
aetiolog
also
pursu
search
streptococcu
pneumonia
l
pneumophila
serogroup
antigen
urin
urinari
antigen
test
binax
acut
convalesc
serum
sampl
week
later
run
parallel
serolog
diagnosi
l
pneumophila
pneumonia
c
pneumonia
coxiella
burnetii
serolog
consid
posit
igm
titr
seroconvers
igg
shown
acut
convalesc
week
avail
singl
sampl
serum
posit
assess
igg
convent
microbiolog
diagnost
method
includ
two
set
blood
cultur
sputum
stain
cultur
detect
pneumonia
l
pneumophila
antigen
urin
patient
method
use
case
viru
bacteria
simultan
identifi
defin
coinfect
two
virus
identifi
cap
defin
dual
vp
order
compar
clinic
laboratori
featur
bp
versu
vp
patient
coinfect
exclud
diagnost
test
admiss
protocolis
physician
charg
includ
patient
respons
perform
appropri
diagnost
test
base
epidemiolog
clinic
characterist
patient
clinic
cours
valu
present
frequenc
qualit
variabl
mean
standard
deviat
sd
continu
normal
distribut
variabl
median
interquartil
rang
normal
distribut
comparison
patient
diagnosi
bp
vp
perform
use
unpair
ttest
utest
appropri
chisquar
use
compar
proport
two
group
statist
signific
taken
pvalu
data
analys
perform
use
spss
softwar
version
accord
aetiolog
diagnosi
case
cap
due
bacteria
due
virus
due
virus
bacteria
coinfect
unknown
aetiolog
figur
show
common
pathogen
patient
diagnos
bp
pneumonia
identifi
patient
remain
bacteri
agent
respons
less
five
case
four
patient
pneumococc
infect
associ
bacteri
agent
c
burnetii
two
pneumonia
one
c
pneumonia
one
patient
contribut
differ
diagnost
method
diagnosi
bp
illustr
tabl
blood
cultur
provid
microbiolog
diagnosi
patient
pneumonia
one
pseudomona
aeruginosa
patient
receiv
immunosuppress
therapi
pneumonia
detect
posit
urinari
antigen
assay
patient
test
among
patient
vp
common
organ
rsv
n
influenza
b
n
two
aetiolog
agent
includ
parainfluenza
rhinoviru
metapneumoviru
coronaviru
fig
four
dual
infect
rsv
virus
two
parainfluenza
one
rhinoviru
one
coronaviru
patient
coinfect
common
combin
pneumonia
rhinoviru
n
follow
pneumonia
coronaviru
n
pneumonia
rsv
n
figur
summaris
frequent
coinfect
design
allow
us
learn
someth
season
respiratori
virus
studi
influenza
rsv
two
frequent
virus
late
autumn
earli
winter
follow
coronaviru
parainfluenza
spring
summer
metapneumoviru
identifi
rhinoviru
found
throughout
year
fig
compar
vp
bp
differ
found
term
age
gender
comorbid
charlson
score
proport
smoker
higher
group
vp
see
tabl
vp
characteris
lower
frequenc
shake
chill
higher
frequenc
myalgia
rhinorrhoea
odynophagia
dri
cough
see
tabl
found
differ
vp
bp
chest
radiograph
characterist
twenti
patient
vp
present
alveolar
consolid
term
laboratori
find
patient
vp
far
like
low
pct
level
bp
also
crp
level
lower
see
tabl
term
sever
curb
score
higher
bp
vp
shock
present
bp
charlson
score
psi
need
mechan
ventil
intens
care
unit
icu
admiss
mortal
similar
group
see
tabl
global
mortal
rate
highest
patient
coinfect
patient
immunosuppress
enrol
two
due
hiv
infect
count
less
one
corticosteroid
treatment
one
treatment
ifn
beta
final
eight
patient
current
antineoplast
agent
followup
immunosuppress
patient
receiv
follow
diagnos
two
vp
one
hivinfect
patient
also
present
immun
reconstitut
inflammatori
syndrom
five
bp
two
mix
infect
three
unknown
etiolog
hivinfect
patient
fibrobronchoscopi
trichom
stain
done
two
immunosuppress
oncolog
patient
die
due
sever
sepsi
bacteraemia
due
pneumococc
infect
first
day
admiss
establish
microbiolog
diagnosi
patient
cap
challeng
although
mani
studi
perform
aetiolog
remain
unknown
approxim
onehalf
case
present
studi
use
pcr
test
ad
convent
microbiolog
method
abl
produc
etiolog
diagnos
repres
increas
number
diagnos
compar
standard
method
quarter
patient
viru
pathogen
isol
recent
studi
also
sought
determin
presenc
respiratori
viru
cap
adult
extens
diagnost
test
report
incid
vp
rang
recent
publish
larg
cohort
similar
rate
coinfect
report
howev
found
smaller
proport
dual
viral
infect
compar
studi
focus
influenzaassoci
cap
role
respiratori
virus
caus
agent
pneumonia
controversi
lieberman
et
al
use
nucleic
acid
amplif
techniqu
provid
data
frequenc
identif
viral
caus
hospitalis
patient
lower
respiratori
tract
infect
compar
find
radiolog
confirm
cap
ambulatori
control
popul
without
respiratori
tract
infect
hospitalis
popul
nonpneumon
lower
respiratori
tract
infect
nplrti
frequenc
viral
cap
patient
compar
control
patient
nplrti
frequenc
viral
cap
put
context
demonstr
virus
even
common
patient
nplrti
frequenc
posit
test
significantli
lower
zero
control
impli
patient
colonis
without
becom
ill
remark
cohort
patient
vp
differ
clinic
present
lower
inflammatori
respons
measur
biomark
observ
support
role
respiratori
virus
cap
distinct
clinic
analyt
featur
present
studi
sputum
sampl
use
instead
nasopharyng
sampl
difficult
obtain
sputum
good
qualiti
nasopharyng
swab
sputum
overcom
extent
potenti
colonis
role
upper
respiratori
tract
optimis
viral
load
lower
respiratori
tract
specimen
obviou
advantag
establish
caus
pneumonia
howev
obtain
reliabl
specimen
contamin
flora
upper
airway
difficult
implement
quantit
test
shed
light
relat
colonis
infect
viru
load
sever
cohort
influenza
rsv
common
caus
vp
adult
previous
report
rsv
increasingli
recognis
caus
respiratori
ill
adult
pulmonari
infect
associ
increas
mortal
howev
rhinoviru
viral
pathogen
frequent
identifi
coinfect
rhinoviru
report
sever
outbreak
sever
respiratori
diseas
fatal
pneumonia
elderli
resid
nurs
home
surprisingli
infrequ
identifi
could
explain
peak
pandem
alreadi
studi
initi
studi
began
week
repres
end
flu
pandem
area
expect
clear
season
pattern
identifi
viral
infect
although
shown
signific
contribut
respiratori
virus
patient
present
pneumonia
pneumonia
remain
lead
caus
agent
one
relev
find
clinic
present
sever
crp
pct
valu
differ
vp
bp
observ
import
clinic
implic
could
help
guid
empir
therapi
absenc
modern
molecular
diagnost
pct
level
use
guid
shorter
cours
antimicrobi
therapi
even
avoid
use
antimicrobi
therapi
lowrisk
patient
nevertheless
exact
role
pct
manag
pneumonia
still
subject
ongo
discuss
debat
clear
consensu
reach
whether
patient
diagnos
viral
cap
need
treat
antibiot
expert
recommend
patient
pneumonia
receiv
antibiot
treatment
exclus
presenc
bacteri
coinfect
difficult
imposs
studi
need
order
valid
result
studi
strength
limit
data
avail
tri
correl
viral
aetiolog
clinic
radiolog
laboratori
featur
cap
strength
studi
prospect
natur
thorough
collect
clinic
laboratori
data
cohort
consecut
patient
admit
singl
institut
systemat
use
modern
molecular
method
diagnosi
also
sever
limit
studi
first
foremost
despit
best
effort
detail
studi
protocol
number
convalesc
serum
specimen
miss
therebi
potenti
underestim
number
case
bp
potenti
underestim
number
coinfect
second
exclud
patient
without
sputum
obtain
specimen
conduct
pcr
test
studi
protocol
violat
third
use
qualit
instead
quantit
pcr
test
final
strictli
speak
studi
confirm
vp
would
requir
lung
tissu
sampl
enrol
patient
howev
may
select
bia
group
vp
bp
distinct
clinic
laboratori
featur
concord
aetiolog
diagnosi
allow
us
suspect
bacteri
versu
viral
caus
sum
multiplex
pcr
test
cap
patient
increas
number
microbiolog
diagnos
allow
identif
viral
infect
onethird
case
howev
pneumonia
still
remain
lead
caus
cap
clinic
present
sever
crp
pct
valu
differ
vp
bp
help
clinician
guid
empir
therapi
